Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2023 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Nov 11, 2022
Slide 1: Cover letter to stock exchanges
11th November, 2022 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Dear Sir(s), Sub: Press Re
Slide 2: Press Release: Alkem reports Q2FY23 and H1FY23 results
Press Release Alkem reports Q2FY23 and H1FY23 results Mumbai, November 11, 2022: Alkem Laboratories Ltd. (Alkem) today announced its standalone and consolidated financial results for the second quarter and six months ended September 30, 2022. These results were taken on record by the Board of Direct
Slide 3: Operational Highlights: Domestic Business
Operational Highlights Domestic Business In Q2FY23, the Company’s India sales grew by 13.0% YoY, recording sales of ₹ 22,161 million as compared to ₹ 19,605 million in Q2FY22. For H1FY23, the Company’s India sales was ₹ 39,976 million compared to ₹ 38,702 million in H1FY22 – growth of 3.3% YoY. As p
Slide 4: International Business and R&D Investments
International Business In Q2FY23, the Company’s International sales grew by 3.0% YoY, recording sales of ₹ 8,291 million as compared to ₹ 8,052 million in Q2FY22. For H1FY23, the Company’s International sales declined by 0.4% to ₹ 15,895 million compared to ₹ 15,955 million in H1FY22. • US sales for
Slide 5: Q2FY23 and H1FY23 Conference Call
Q2FY23 and H1FY23 Conference Call at 5:00pm IST, November 11, 2022 Alkem will organize a conference call for investors and analysts on Friday, November 11, 2022 from 5:00 pm to 6:00 pm IST to discuss its Q2FY23 and H1FY23 financial results. Alkem will be represented on the call by Mr. Sandeep Singh,
Slide 6: Investor Presentation Q2FY23
Investor Presentation Q2FY23 November 11, 2022
Slide 7: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 8: Key Highlights of Q2FY23
Key Highlights of Q2FY23 • Revenue from Operations grew by 10.0% YoY during the quarter, with EBITDA margin of 14.7% and Net Profit margin of 10.7% • India Business: As per IQVIA,Company’s sales in Q2FY23 registered growth of 13.2% YoY compared to IPM growth of 8.2% YoY • Market beating performance
Slide 9: Key Financial Highlights – Q2FY23 (Consolidated)
Key Financial Highlights – Q2FY23 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 22,161 19,605 30,793 28,000 QFY22 Q2FY23 International sales 8,052 8,291 Q2FY22 QFY23 Q2FY22 Q2FY23
Slide 10: Key Financial Highlights – Q2FY23 (Consolidated)
Key Financial Highlights – Q2FY23 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 17,425 17,724 6,244 4,539 62.2% 57.6% 22.3% 14.7% Q2FY22 Q2FY23 Q2FY22 Q2FY23 PBT (before Minority Interest) PAT (after Minority Interest) 5,443 5,815 3,308 4,023 Q2FY22 Q2FY23
Slide 11: Key Financial Highlights – H1FY23 (Consolidated)
Key Financial Highlights – H1FY23 (Consolidated) All figures in ₹ mn Particulars (₹ mn) H1FY23 H1FY22 YoY growth Revenue from Operations 56,558 55,314 2.2% Gross Profit 32,534 33,791 -3.7% Gross Profit margin 57.5% 61.1% EBITDA 6,572 12,172 -46.0% EBITDA margin 11.6% 22.0% PBT 5,542 11,377 -51.3% PB
Slide 12: India Business
India Business India Business: Q2FY23 Sales of ₹ 22,161 million (13.0% YoY growth) • India sales contributed 72.8% to total sales in Q2FY23 • As per IQVIA, In Q2FY23, the Company’s secondary sales grew by 13.2% compared to IPM growth of 8.2% YoY. • Outperformance in acute therapies was mainly led by
Slide 13: Secondary Sales Performance
Secondary Sales Performance Market beating performance across major therapeutic segments in Q2FY23 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 22.7% 19.2% 12.5% 11.6% 11.5% 7.8% 7.2% 6.4% Alkem sales growth YoY1,2 Indian pharm
Slide 14: US Business
US Business US Business: Q2FY23 Sales of ₹ 6,040 million (YoY decline of 0.9%) • US sales contributed 19.8% to total sales in Q2FY23 • During the quarter, the US business registered sequential growth of 8.5% over Q1FY23 • In Q2FY23, the Company filed 3 ANDAs with the US FDA and received 4 approvals
Slide 15: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Received 1 observation. The Company has already submitted a detailed Indore Formulations July 2022 response to the US FDA on the corrective and preventive actions it is taking to address them. Re
Slide 16: Other International Business
Other International Business Other International Business: Q2FY23 Sales of ₹ 2,251 million (15.2% YoY growth) • Other International Market sales contributed 7.4 % to total sales in Q2FY23 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets li
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2022 Non-Institution, 22.65% Promoter & Promoter Group, 57.16% Institution, 20.19% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 18: Thank You
Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com